Background: Doxycycline (DOX) is used in treating a bacterial infection, especially for
Objective: To reduce irritation of DOX for subgingival administration and increase the chemical
stability and against enzymatic, the complex of α-cyclodextrin with DOX was prepared and loaded
into injectable in situ forming implant based on PLGA.
Methods: FTIR, molecular docking studies, X-ray diffraction, and differential scanning calorimetry
was performed to characterize the DOX/α-cyclodextrin complex. Finally, the in-vitro drug release
and modeling, morphological properties, and cellular cytotoxic effects were also evaluated.
Results: The stability of DOX was improved with complex than pure DOX. The main advantage of
the complex is the almost complete release (96.31 ± 2.56 %) of the drug within 14 days of the implant,
whereas in the formulation containing the pure DOX and the physical mixture the DOX with
α-cyclodextrin release is reached to 70.18 ± 3.61 % and 77.03 ± 3.56 %, respectively. This trend is
due to elevate of DOX stability in the DOX/ α-cyclodextrin complex form within PLGA implant
that confirmed by the results of stability.
Conclusion: Our results were indicative that the formulation containing DOX/α-cyclodextrin complex
was biocompatible and sustained-release with minimum initial burst release.